PML/RARA AML M3 APML Genetic Test
Understanding Acute Promyelocytic Leukemia Testing
The PML/RARA AML M3 APML genetic test represents a critical advancement in hematologic oncology diagnostics, specifically designed to detect Acute Promyelocytic Leukemia (APL), classified as AML-M3 in the French-American-British classification system. This specialized test identifies the unique genetic signature that characterizes this distinct leukemia subtype, enabling precise diagnosis and targeted treatment approaches.
What Does the PML/RARA Test Measure?
This sophisticated genetic analysis detects the specific chromosomal translocation t(15;17), which results in the fusion of the PML (Promyelocytic Leukemia) gene on chromosome 15 with the RARA (Retinoic Acid Receptor Alpha) gene on chromosome 17. This abnormal genetic rearrangement creates the PML/RARA fusion gene, which disrupts normal cellular differentiation and promotes uncontrolled growth of promyelocytes in the bone marrow.
- Detection of t(15;17) chromosomal translocation
- Identification of PML/RARA fusion gene expression
- Confirmation of Acute Promyelocytic Leukemia diagnosis
- Monitoring of minimal residual disease during treatment
- Assessment of treatment response and potential relapse
Who Should Consider PML/RARA Testing?
This genetic test is essential for individuals presenting with clinical symptoms suggestive of Acute Promyelocytic Leukemia or those with abnormal blood counts requiring further investigation.
Clinical Indications and Symptoms
- Unexplained bleeding tendencies or excessive bruising
- Persistent fatigue and weakness
- Recurrent infections and fever
- Abnormal blood counts showing pancytopenia
- Bone pain or discomfort
- Unexplained weight loss
- Enlarged liver or spleen
- Patients with suspected acute myeloid leukemia
Benefits of PML/RARA Genetic Testing
Early and accurate detection of the PML/RARA fusion gene provides numerous clinical advantages for patients and healthcare providers.
Key Advantages
- Precise Diagnosis: Confirms APL diagnosis with high specificity
- Targeted Therapy: Enables treatment with all-trans retinoic acid (ATRA)
- Improved Outcomes: Early detection significantly increases survival rates
- Treatment Monitoring: Tracks response to therapy and detects relapse
- Risk Stratification: Helps determine appropriate treatment intensity
- Genetic Counseling: Provides valuable information for family planning
Understanding Your Test Results
Interpreting PML/RARA test results requires careful consideration of clinical context and laboratory findings.
Result Interpretation Guidelines
- Positive Result: Indicates presence of PML/RARA fusion gene, confirming APL diagnosis
- Negative Result: Suggests absence of the characteristic genetic abnormality
- Quantitative Results: May indicate the percentage of cells carrying the fusion gene
- Follow-up Testing: Regular monitoring may be recommended during treatment
- Clinical Correlation: Results should be interpreted alongside other laboratory findings
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | PML/RARA AML M3 APML Genetic Test |
| Regular Price | $176 USD |
| Discount Price | $132 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Bone Marrow / Peripheral Blood |
| Test Components | Sodium Heparin Vacutainer (2ml) |
| Methodology | FISH (Fluorescence In Situ Hybridization) |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing services nationwide.
Book Your Genetic Test Today
Take the first step toward accurate leukemia diagnosis and personalized treatment. Our experienced genetic counselors and oncology specialists are ready to assist you with comprehensive testing and result interpretation.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your PML/RARA AML M3 APML genetic test. Early detection saves lives, and our rapid 3-4 day turnaround ensures you receive critical diagnostic information when you need it most.
Important Pre-Test Information
The PML/RARA AML M3 APML genetic test requires a physician’s prescription for diagnostic purposes. Please note that prescriptions are not applicable for surgical procedures, pregnancy cases, or individuals planning international travel. Consult with your healthcare provider to determine if this test is appropriate for your clinical situation.
